Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. (NASDAQ: ICCM) filed a Form 6-K on 25 June 2025 reporting that it has furnished a press release entitled “IceCure Announces Record Date for Rights Offering for Up to $10 Million.” The press release, provided as Exhibit 99.1, is incorporated by reference into the company’s existing registration statements on Forms F-3 (Nos. 333-258660 & 333-267272) and S-8 (Nos. 333-270982, 333-264578, 333-262620 & 333-281587). The filing contains no financial statements, earnings data or detailed terms of the rights offering.
The company indicates only that a record date has been set for shareholders to participate in a rights offering of up to $10 million. If completed, this capital raise would provide additional liquidity while allowing existing shareholders to maintain proportional ownership by exercising their rights. However, subscription price, ratio, and expected closing date are not disclosed in this document. The report was signed by Chief Executive Officer Eyal Shamir.
IceCure Medical Ltd. (ICCM) has filed Amendment No. 1 to its Form F-1 to launch a non-transferable rights offering that could raise up to US$10 million. Existing holders of the company’s ordinary shares as of the July 9, 2025 record date will receive one subscription right for every share owned. Each right allows the purchase of 0.1703 of a Unit at a subscription price of US$1.00 per Unit. A full Unit comprises one ordinary share and one five-year warrant exercisable at US$1.00. Because 0.1703 of a Unit is issued per right, shareholders must aggregate at least six rights to obtain one complete Unit; holders of fewer than six shares will be unable to participate.
The subscription period runs from July 10 to 5:00 p.m. ET on July 28, 2025. Unexercised rights will expire worthless unless the company extends the offering. Investors who fully exercise their basic rights may request additional Units under an over-subscription privilege, subject to proration.
Capital Structure: If fully subscribed, IceCure will issue up to 10 million Units consisting of either 10 million ordinary shares or, at investors’ option to avoid ownership limits, 10 million pre-funded warrants (exercise price US$0.0001) plus 10 million accompanying warrants. All warrants carry a call feature that can be triggered once ProSense breast-cancer marketing authorization is publicly announced and the share VWAP equals or exceeds 300 % of the exercise price for 30 consecutive trading days.
Back-stop Commitment: Epoch Partner Investments Limited, already holding 44.04 % of IceCure’s shares, has provided a standby commitment to purchase up to US$5 million of Units through basic and over-subscription privileges.
Use of Proceeds: Net proceeds, together with existing cash and investments, are earmarked to repay a Bridge Loan ("Loan Amount") and for general corporate and working-capital purposes.
Maxim Group LLC will act as dealer-manager on a best-efforts basis, and Broadridge Corporate Issuer Solutions, LLC is the subscription agent holding investor funds in escrow until completion or cancellation of the offering.